← Cockpit
242_048predictionBiotech/LongevityAI-scaling

FDA will move to zero clinical trial model given enough Bayesian/computational evidence

Predictor: Alex Wissner-Gross · ep#242 "Elon Enters the Chip Race, the S&P 500 Repricing, and Human Drivers Will Become Illegal | EP #242" · source

Prior probability
45.0%
Current probability
36.4%
evolves via intake + LBP
Conviction
3/5
Signal quality
C
Resolution
pending
Window
2026-01-01 – 2031-09-30
Edges in / out
10 / 5
Tickers exposed
38

Prediction text

FDA will move to zero clinical trial model given enough Bayesian/computational evidence | I think we would see similar developments from the FDA to go to a zero clinical trial model given enough Bayesian evidence and given enough computational evidence

Verbatim quote

From episode "Elon Enters the Chip Race, the S&P 500 Repricing, and Human Drivers Will Become Illegal | EP #242"
I think we would see similar developments from the FDA to go to a zero clinical trial model given enough Bayesian evidence and given enough computational evidence

Predictor: Alex Wissner-Gross

κ + Brier as of 2026-05-22
κ (discount)
0.844
Brier
0.0341
excellent
Hits / Misses
6 / 1
of 11 resolved
Hit rate
54.5%
Calibration plot (stated vs observed)

Evidence about this node from Alex Wissner-Gross is multiplied by κ in /api/intake. Lower κ = less weight; floors at 0.10 (effectively silenced) and caps at 1.00 (full weight).

Reference class: fda_breakthrough_label

Linked via embedding similarity 0.636

FDA breakthrough designation → approval within 4 years

Base rate
39.0%
78/200 historical
Inside weight
0.340
TRF=0.94
Outside weight
0.660
pulling toward base rate
inside 31.5% → blend 36.4% 4.9pp)

Tetlock-style outside view: at TRF=1 (just predicted), outside view dominates (w_in=0.3). At TRF=0 (deadline), inside view dominates (w_in=1.0). The blend regularizes overconfident inside views toward the historical base rate.

Probability over time

5 prob_history rows
0%25%50%75%100%prior 45%2026-04-302026-04-302026-04-30
intake v2milestone miss sweeplbp propagationreference class assignedlegacy v1prior_prob (analyst seed)current = 36.4%

Milestone chain

Pre-event signals (upstream prereqs + window checkpoints) → resolution event → downstream cascades. Status/dates update from linked nodes; re-derive nightly via scripts/ops/derive_milestones.py.
Leading chain: 7 fired ✓ · 2 pending
  1. 2026-01-31hitFDA + EMA publish joint Guiding Principles of Good AI Practice (Jan 2026)
    How: CDER co-publishes 10 Guiding Principles for AI in drug development with EMA
    Source: deep_research_enrichedconf 92%
  2. 2026-03-31hitEMA issues first qualification opinion on an AI-methodology virtual control arm
    How: European Medicines Agency formally qualifies an AI digital-twin methodology for use in pivotal trials
    Source: deep_research_enrichedconf 82%
  3. 2026-04-15hitSanofi or peer eliminates a Phase 2 cohort in a regulatory submission using virtual patient models
    How: Top-20 pharma sponsor publicly confirms Phase 2 was conducted with AI virtual control arm in lieu of placebo cohort
    Source: deep_research_enrichedconf 75%
  4. 2027-01-01 → 2028-12-31pendingFirst FDA pivotal approval where Phase 3 control arm is fully replaced by digital twin
    How: FDA grants approval based on a Phase 3 with no concurrent placebo arm (only AI/Bayesian historical controls)
    Source: deep_research_enrichedconf 50%
  5. 2029-01-01 → 2031-09-30pendingFirst sub-indication approved with zero traditional clinical trials (computational + Bayesian only)
    How: FDA grants narrow indication approval whose primary evidence package is fully in-silico (digital twin + Bayesian RWE)
    Source: deep_research_enrichedconf 30%

What if this resolves?

Clamp this prediction TRUE or FALSE and run a counterfactual Gibbs sample. Surfaces the predictions whose marginals shift most under that assumption.
(live posterior: 36%)

Click a button to clamp this prediction and run a Gibbs sample. Returns the predictions whose marginals shift most. ~30s per run; ideal for stress-testing "if X resolves, what else moves?"

Evidence chain

Every probability update with full Bayesian provenance — chronological, latest first
legacy v12026-04-30T19:17:54Z36.4%-2.9pp
intake:99aa73db-75b1-4b1e-8470-a11f87b23937 bayesian_v2 inside=0.315 blend=0.364 LLR=-0.342 κ=0.84 w_in=0.34 fda_breakthrough_label
LBP2026-04-30T16:39:51Z39.3%-1.7pp
Network propagation: 41.0% → 39.3%
5-iter LBP, residual 0.00825 · damping 0.5, w_intrinsic 0.5 · method lbp_v2 · run 0c8a4ea3
legacy v12026-04-30T16:13:50Z41.0%+1.2pp
reference_class_assigned bayesian_v2 inside=0.450 blend=0.410 w_in=0.34 fda_breakthrough_label
LBP2026-04-30T02:18:57Z39.8%-1.2pp
Network propagation: 41.0% → 39.8%
5-iter LBP, residual 0.00825 · damping 0.5, w_intrinsic 0.5 · method lbp_v1 · run 592311ef
legacy v12026-04-30T01:56:50Z41.0%-4.0pp
reference_class_assigned bayesian_v2 inside=0.450 blend=0.410 w_in=0.34 fda_breakthrough_label

Network propagation neighbors

Top edges sorted by latest LBP cross-impact
All propagation →

Top incoming (parents)

Edges that influence THIS node's belief

KindNodeTheir probP(c|s=T)P(c|s=F)Δ implied
killerTK09
Energy Grid Cap (Data Center Power Wall)
35.0%0.0500.450-0.054
killerTK03
AI Regulatory Moratorium (EU/US Capability Freeze)
10.0%0.0500.450+0.046
prereqSEM_015
Nvidia agreed to remit 15% of China chip-sale revenue directJensen Huang
66.3%0.4500.050-0.045
prereqSEM_027
Nvidia Data Center revenue +66% YoY, contributing ~90% of $5Joseph Moore
68.3%0.4500.050-0.045
killerTK02
AI Compute Supply Shock (TSMC/Taiwan Disruption)
12.0%0.0500.450+0.038

Top outgoing (children)

Predictions THIS node influences

KindNodeTheir probP(c|s=T)P(c|s=F)Δ implied
prereq230_024
Under a certain age (40-50) life expectancy is infinity due Dave Blundin
39.6%0.6000.050-0.146
prereq242_023
World will have 10x more wealth around 2034-2036Dave Blundin
34.2%0.6000.050-0.092
prereq246_016
Dragonfly nuclear-powered octicopter arrives at Titan in 203Peter Diamandis
35.6%0.6500.050-0.088
prereq230_020
Peter's 14-year-old son Milan will never get a driver's licePeter Diamandis
34.7%0.6500.050-0.079
prereq240_036
TEPCO's restarted reactor will support 20% of Japan's electrPeter Diamandis
34.3%0.6500.050-0.075

Ticker exposure

38 ticker(s) linked

Beneficiaries (24)

NBISNVDAPLABEQIXAPLDASMIYASMLWULFIRENALABMUCRWVAMZNMSFTSTXSFTBYDELLAMTORCLGOOGLAAPLIRMLNVGYMETA

Adverse (6)

IBMACNCHGGGENLRNWNS

Prerequisites (10)

Predictions that must hit first
TypePredTitleDomainLag
prereqSEM_011Nvidia became the world's first $5 trillion company (late 2025), operating a near-monopoly on advanced AI chips.Capital Markets
prereqSEM_027Nvidia Data Center revenue +66% YoY, contributing ~90% of $57B fiscal Q3 revenue; >$4.5T market cap entirely underpinned by AI silicon.Capital Markets
prereqSEM_014Nvidia's Arizona-based TSMC factory successfully fabricated cutting-edge semiconductors on US soil for first time in decades (October 2025).Manufacturing
prereqSEM_012Nvidia quadrupled chip production output while only doubling human headcount — achieved by deploying AI coding tools (Cursor, Claude Code) across engineering.AI/Manufacturing
prereqSEM_015Nvidia agreed to remit 15% of China chip-sale revenue directly to US government in exchange for reversing specific AI chip export bans.Policy/Semis
killerTK09Energy Grid Cap (Data Center Power Wall)
killerTK05Rate Regime Persistence (10y > 5% through 2028)
killerTK01AGI Capability Plateau (2026-27 Training Stall)
killerTK02AI Compute Supply Shock (TSMC/Taiwan Disruption)
killerTK03AI Regulatory Moratorium (EU/US Capability Freeze)

Dependents (5)

Predictions enabled by this
TypePredTitleDomainLag
prereq230_020Peter's 14-year-old son Milan will never get a driver's license.Auto/Transport
prereq246_016Dragonfly nuclear-powered octicopter arrives at Titan in 2034.Space
prereq240_036TEPCO's restarted reactor will support 20% of Japan's electric needs by 2040Energy
prereq242_023World will have 10x more wealth around 2034-2036Macro/Economy
prereq230_024Under a certain age (40-50) life expectancy is infinity due to longevity escape velocity.Biotech/Longevity

Linked documents (10)

Auto-generated by cosine similarity from Polymarket / Manifold / EDGAR / GDELT
SimSourceTitleMarket probPolarityReviewedPublished
0.666fdaFDA ANDA211182: ANDA211182 ((unspecified)) — HETERO LABS LTD Vmentionspending2026-04-16
0.663arxivOptimizing Social Utility in Sequential Experimentsmentionspending2026-05-07
0.662arxivUncertainty-Aware Prediction of Lung Tumor Growth from Sparse Longitudinal CT Data via Bayesian Physics-Informed Neural Networksmentionspending2026-05-13
0.660fdaFDA ANDA213405: LENALIDOMIDE (LENALIDOMIDE) — TORRENTmentionspending2026-04-27
0.659fdaFDA ANDA215356: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — AUROBINDO PHARMA LTDmentionspending2026-06-03
0.658fdaFDA ANDA212414: LENALIDOMIDE (LENALIDOMIDE) — HETERO LABS LTD Vmentionspending2026-04-27
0.653fdaFDA ANDA212336: ANDA212336 ((unspecified)) — DR REDDYS LABS LTDmentionspending2026-05-07
0.652fdaFDA ANDA220137: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SOMERSET THERAPS LLCmentionspending2026-06-03
0.648fdaFDA NDA021880: REVLIMID (LENALIDOMIDE) — BRISTOL MYERS SQUIBBmentionspending2026-04-27
0.647fdaFDA ANDA204345: CAPECITABINE (CAPECITABINE) — DR REDDYSmentionspending2026-05-07

Raw metadata

From Thesis_Timeline_v1.0_FINAL workbook
{
  "nia": false,
  "qty": "0 clinical trials",
  "url": "https://www.youtube.com/watch?v=wMLcIWLlcWg",
  "mode": "PREDICTION",
  "role": "Host",
  "caveats": "barring exceptional circumstance",
  "context": "the FDA to go to a zero clinical trial model given enough Bayesian evidence",
  "to_year": 2031,
  "verbatim": "I think we would see similar developments from the FDA to go to a zero clinical trial model given enough Bayesian evidence and given enough computational evidence",
  "conv_cues": "I think",
  "direction": "HAPPEN",
  "from_year": 2026,
  "timeframe": "~5 years",
  "conv_level": "MEDIUM",
  "milestones": [
    {
      "kind": "llm_pre_event",
      "label": "FDA + EMA publish joint Guiding Principles of Good AI Practice (Jan 2026)",
      "source": "deep_research_enriched",
      "status": "hit",
      "weight": 0.4,
      "ordinal": -9,
      "source_id": null,
      "confidence": 0.92,
      "source_url": "https://www.appliedclinicaltrialsonline.com/view/understanding-fda-ema-guidance-ai-digital-twin-applications-trials",
      "expected_date": "2026-01-31",
      "observed_date": "2026-01-31",
      "research_origin": "deep_research",
      "measurement_criterion": "CDER co-publishes 10 Guiding Principles for AI in drug development with EMA"
    },
    {
      "kind": "llm_pre_event",
      "label": "EMA issues first qualification opinion on an AI-methodology virtual control arm",
      "source": "deep_research_enriched",
      "status": "hit",
      "weight": 0.4,
      "ordinal": -8,
      "source_id": null,
      "confidence": 0.82,
      "source_url": "https://www.pienomial.com/blog/digital-twins-in-clinical-trials-how-ai-generated-virtual-control-arms-are-rewriting-study-design-in-2026",
      "expected_date": "2026-03-31",
      "observed_date": "2026-03-31",
      "research_origin": "deep_research",
      "measurement_criterion": "European Medicines Agency formally qualifies an AI digital-twin methodology for use in pivotal trials"
    },
    {
      "kind": "llm_pre_event",
      "label": "Sanofi or peer eliminates a Phase 2 cohort in a regulatory submission using virtual patient models",
      "source": "deep_research_enriched",
      "status": "hit",
      "weight": 0.4,
      "ordinal": -7,
      "source_id": null,
      "confidence": 0.75,
      "source_url": "https://intuitionlabs.ai/articles/digital-twins-clinical-trials-virtual-control-arms",
      "expected_date": "2026-04-15",
      "observed_date": "2026-04-15",
      "research_origin": "deep_research",
      "measurement_criterion": "Top-20 pharma sponsor publicly confirms Phase 2 was conducted with AI virtual control arm in lieu of placebo cohort"
    },
    {
      "kind": "prereq",
      "label": "Nvidia became the world's first $5 trillion company (late 2025), operating a near-monopoly on advanced AI chips.",
      "status": "hit",
      "weight": 0.5,
      "ordinal": -6,
      "source_id": "SEM_011",
      "expected_date": "2026-04-29",
      "observed_date": "2026-04-29"
    },
    {
      "kind": "prereq",
      "label": "Nvidia Data Center revenue +66% YoY, contributing ~90% of $57B fiscal Q3 revenue; >$4.5T market cap entirely underpinned by AI silicon.",
      "status": "hit",
      "weight": 0.5,
      "ordinal": -5,
      "source_id": "SEM_027",
      "expected_date": "2026-04-29",
      "observed_date": "2026-04-29"
    },
    {
      "kind": "prereq",
      "label": "Nvidia's Arizona-based TSMC factory successfully fabricated cutting-edge semiconductors on US soil for first time in decades (October 2025).",
      "status": "hit",
      "weight": 0.5,
      "ordinal": -4,
      "source_id": "SEM_014",
      "expected_date": "2026-04-29",
      "observed_date": "2026-04-29"
    },
    {
      "kind": "prereq",
      "label": "Nvidia quadrupled chip production output while only doubling human headcount — achieved by deploying AI coding tools (Cursor, Claude Code) a",
      "status": "hit",
      "weight": 0.5,
      "ordinal": -
... (truncated)